Which glycoprotein IIb/IIIa antagonists have been shown to be beneficial for the treatment of unstable angina in high risk patients?

Updated: Oct 01, 2020
  • Author: Walter Tan, MD, MS; Chief Editor: Eric H Yang, MD  more...
  • Print

Of the currently used GP IIb/IIIa inhibitors, only eptifibatide and tirofiban have been shown to be beneficial in high-risk patients treated with medical management alone. The relative reduction in adverse events observed in this setting is on the order of 5-7%. In addition, a meta-analysis of 6 randomized trials (with 31,400 patients) failed to show a mortality benefit in patients who did not undergo PCI. [58] Whether this small benefit offsets the risk of bleeding events is a matter for the physician’s clinical judgment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!